BiotechTube

Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent Chemotherapy

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hormone Receptor Positive Breast Cancer

Conditions

Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer

Trial Timeline

May 23, 2016 → Nov 9, 2023

NCT ID
NCT02675231

About Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent Chemotherapy

Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent Chemotherapy is a phase 2 stage product being developed by Eli Lilly for Hormone Receptor Positive Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02675231. Target conditions include Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02675231Phase 2Completed

Competing Products

20 competing products in Hormone Receptor Positive Breast Cancer

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
77
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
23
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open LabelAstellas PharmaPhase 3
77
Enzalutamide + PlaceboAstellas PharmaPhase 3
77
YM598Astellas PharmaPhase 2
52
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
52
PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropinSun PharmaceuticalPhase 3
77
ONO-4578 + letrozole + Palbociclib + abemaciclibOno PharmaceuticalPhase 1
33
Somatropin + SomatropinEli LillyPhase 3
77
Somatropin + SomatropinEli LillyPhase 3
77
Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
85
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
33
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
33
SHR7280Jiangsu Hengrui MedicinePhase 1
33

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85